glp-1 drugs from the Gray Market GLP1 Drug Use For Weight

This review provides an analysis of GLP-1 RAs and their multi-agonist derivatives as therapeutic agents for MASLD, examining their biological mechanisms and clinical efficacy based on current evidence

N Engl J Med (2021) 385:896907

The Role of GIP Receptor in the CNS for the Pathogenesis of Obesity

Exploring the GLP-1-GLP-1R axis in porcine pancreas and gastrointestinal tract in vivo by ex vivo autoradiography

Diabetic kidney disease, a common complication in patients with type 2 diabetes mellitus, is associated with a markedly increased morbidity and mortality, especially of cardiovascular origin, and faster progression to end-stage renal disease

Originally developed for managing blood glucose levels in people with type 2 diabetes, GLP-1 receptor agonists like Ozempic have demonstrated impressive results in supporting healthy weight loss